<DOC>
	<DOCNO>NCT02181998</DOCNO>
	<brief_summary>The primary objective ASSENT 3 Plus ( ASSENT 3 ) evaluate safety efficacy full dose tenecteplase combine unfractionated heparin ( UFH , group A ) full dose tenecteplase combine enoxaparin ( ENOX , group B ) . An additional objective ASSENT 3 Plus describe different time interval prehospital phase .</brief_summary>
	<brief_title>A Trial Efficacy Safety Full Dose Tenecteplase Combined With Unfractionated Heparin ( UFH ) Enoxaparin Acute Myocardial Infarction ( AMI ) Prehospital Setting</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Tenecteplase</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Onset symptom AMI within six hour prior randomisation A 12lead ECG one following : STsegment elevation ≥ 0.1 millivolt ( mV ) two limb lead , ≥ 0.2 mV two contiguous precordial lead indicative AMI , leave bundlebranch block Age ≥ 18 Informed consent receive Hypertension define blood pressure ( BP ) &gt; 180/110 mmHg ( systolic blood pressure ( SBP ) 180 mmHg and/or diastolic blood pressure ( DBP ) &gt; 110 mmHg ) repeat measurement current admission prior randomisation Use abciximab ( ReoPro ® ) glycoproteinIIb/IIIa antagonist within precede seven day Major surgery , biopsy parenchymal organ , significant trauma within two month Any minor head trauma trauma occur onset current myocardial infarction ( MI ) Any known history stroke transient ischaemic attack dementia Any known structural damage central nervous system Prolonged cardiopulmonary resuscitation ( &gt; 10 min ) previous two week Current oral anticoagulation Standard UFH ( heparin sodium ) &gt; 5000 international unit ( IU ) , subcutaneous ( SC ) therapeutic dose low molecular weight heparin ( LMWH ) within six hour randomisation Known thrombocytopenia ( prior platelet count 100 000 cells/μL ( 100 x 10**9/L ) ) Known renal insufficiency ( prior Screatinine &gt; 2.5 mg % ( &gt; 220 μmol/L ) men 2.0 mg % ( &gt; 175 μmol/L ) ) woman Pregnancy lactation , parturition within previous 30 day . Women childbearing potential negative pregnancy test , use medically accept method birth control Treatment investigational drug another study protocol past seven day Previous enrolment study Known sensitivity tenecteplase , tissue plasminogen activator ( tPA ) , abciximab , heparin LMWH Any condition investigator felt would place patient increase risk investigational therapy initiate ( e.g . know haemorrhagic diathesis , acute pericarditis and/or subacute bacterial endocarditis , acute pancreatitis , severe hepatic dysfunction , diabetic haemorrhagic retinopathy haemorrhagic ophthalmic condition , active peptic ulceration , arterial aneurysm know arterial/venous malformation , neoplasm increase bleed risk ) Inability follow protocol comply followup requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>